Video

Outcomes of the JAVELIN Bladder 100 Trial

Author(s):

Jeanny B. Aragon-Ching, MD, FACPSrikala Sridhar, MD, MSc, FRCPC

Jeanny B. Aragon-Ching, MD, FACP, describes the outcomes of the JAVELIN Bladder 100 study that she presented at ESMO 2022.

Related Videos
Guru P. Sonpavde, MD
Andrea Necchi, MD, associate professor, oncology, Vita-Salute San Raffaele University, director, Genitourinary Medical Oncology, IRCCS San Raffaele Hospital and Scientific Institute
John K. Lee, MD, PhD
Andrea Necchi, MD, associate professor, oncology, Vita-Salute San Raffaele University, director, Genitourinary Medical Oncology, IRCCS San Raffaele Hospital and Scientific Institute
Dingwei Ye, MD, PhD
Dingwei Ye, MD, PhD
Terence W. Friedlander, MD
Joshua Linscott, MD, PhD
Terence W. Friedlander, MD,
Bernard H. Bochner, MD, FACS
Related Content
urothelial cancer | Image Credit: © freshidea - stock.adobe.com
October 8th 2024

Phase 3 Study of TAR-200/Cetrelimab Is Discontinued in MIBC

Oncology Unplugged
August 7th 2024

Park and Grivas Expand on Treatment Updates in Bladder Cancer

Dingwei Ye, MD, Fudan University Shanghai Cancer Center
September 24th 2024

BL-B01D1 Shows Preliminary Efficacy, Safety in Pretreated Advanced Urothelial Carcinoma

Oncology Unplugged
July 24th 2024

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

Guru Sonpavde, MD, assistant director, Clinical Research Unit, Christopher K. Glanz Chair of Bladder Cancer Research, AdventHealth Cancer Institute
September 23rd 2024

QOL Benefits With Nivolumab, Challenges with Sacituzumab Govitecan Characterize Bladder Cancer Management Updates

Andrea Necchi, MD
September 16th 2024

Neoadjuvant TAR-200/Cetrelimab Combo Shows Activity in Muscle-Invasive Bladder Cancer